Srinivas Kota, MD
Internal Medicine · Bolingbrook, ILNPI 1659481562
Payments from drug & device makers
Across 286 payments — averaging $12.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nestle Healthcare Nutrition Inc.$640
- AstraZeneca$583
- Aimmune Therapeutics, Inc.$428
- AbbVie$387
- Lilly USA, LLC$297
- Novo Nordisk$215
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,636100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nestle Healthcare Nutrition Inc. | 63 | $640 |
| AstraZeneca | 39 | $583 |
| Aimmune Therapeutics, Inc. | 44 | $428 |
| AbbVie(2 entities) | 34 | $387 |
| Lilly USA, LLC | 21 | $297 |
| Novo Nordisk | 15 | $215 |
| Amgen | 14 | $214 |
| Merck | 10 | $143 |
| Boehringer Ingelheim | 6 | $121 |
| Arbor Pharmaceuticals, Inc. | 8 | $116 |
| Amarin Pharma, Inc. | 5 | $97 |
| GSK | 6 | $88 |
| Eisai Inc. | 3 | $51 |
| Johnson & Johnson | 3 | $48 |
| Dexcom, Inc. | 3 | $42 |
| Abbott | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Avion Pharmaceuticals | 1 | $12 |
How this compares
$3,642 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $40,856 |
| EliquisApixaban | 80 | $35,624 |
| JardianceEmpagliflozin | 18 | $32,645 |
| JanuviaSitagliptin Phosphate | 34 | $27,266 |
| RybelsusSemaglutide | 17 | $22,059 |
| XareltoRivaroxaban | 33 | $15,742 |
| LinzessLinaclotide | 11 | $10,420 |
| Mesalamine DrMesalamine | 11 | $4,338 |
| Levothyroxine Sodium | 146 | $2,091 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,084 |
| Atorvastatin Calcium | 138 | $1,717 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,687 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $1,661 |
| Potassium Chloride | 63 | $1,364 |
| Metoprolol Succinate | 59 | $1,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $215 | $62,91543 claims |
| Boehringer IngelheimJardiance | $121 | $32,64518 claims |
| MerckJanuvia | $143 | $27,26634 claims |
| Johnson & JohnsonXarelto | $48 | $15,74233 claims |
| AbbVieLinzess | $387 | $10,42011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Bolingbrook
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.